WallStSmart
CSTL

Castle Biosciences Inc

NASDAQ: CSTL · HEALTHCARE · DIAGNOSTICS & RESEARCH

$24.49
+1.03% today

Updated 2026-04-30

Market cap
$734.37M
P/E ratio
P/S ratio
2.13x
EPS (TTM)
$-0.83
Dividend yield
52W range
$15 – $44
Volume
0.4M

Castle Biosciences Inc (CSTL) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+25.1%
Last 4 quarters
Revenue YoY growth
+0.8%
Most recent quarter
EPS YoY growth
-125.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+19.6%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+38.9%
2025-08-04
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-26$-0.08+75.0%$30.83$29.57-4.1%
2025-11-03$-0.02+96.2%$25.50$31.63+24.0%
2025-08-04$0.15+129.4%$14.65$20.35+38.9%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.32$-0.08+75.0%$87.01M+0.8%
2025-09-30$-0.52$-0.02+96.2%$83.04M-3.2%
2025-06-30$-0.51$0.15+129.4%$86.19M-0.9%
2025-03-31$-0.07$-0.90-1275.2%$87.99M+20.6%
2024-12-31$0.04$0.32+700.0%$86.31M+30.5%
2024-09-30$-0.06$0.08+233.3%$85.78M+39.5%
2024-06-30$-0.27$0.31+214.8%$87.00M+73.5%
2024-03-31$-0.33$-0.09+72.7%$72.97M
2023-12-31$-0.54$-0.10+81.5%$66.12M
2023-09-30$-0.76$-0.26+65.8%$61.49M
2023-06-30$-0.91$-0.70+23.1%$50.14M

Frequently asked questions

Has Castle Biosciences Inc beaten earnings estimates?
Castle Biosciences Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +25.1% over the last 4 quarters.
How does CSTL stock react to earnings?
CSTL stock has moved an average of +19.6% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Castle Biosciences Inc's revenue growth rate?
Castle Biosciences Inc reported year-over-year revenue growth of +0.8% in its most recent quarter, with EPS growing -125.0% year-over-year.